Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan in Paroxysmal Atrial Fibrillation
NCT00352560Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2006
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Irbesartan with Placebo (2 arms). Primary endpoint: Atrial Effective Refractory Period at 31 days. Started Jul 2006; status: completed.
02
Drugs
irbesartan
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00352560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00352560.